Date: 2013-09-25
Type of information: Services contract
Compound: Managed Access Program for APN311
Company: Apeiron Biologics (Austria) Idis (UK - USA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
services
Action mechanism:
Disease: high-risk neuroblastoma
Details: * On September 25, 2013, Apeiron Biologics has announced that it has retained the services of Idis Ltd to initiate a Managed Access Program for its product APN311 (ch14.18/CHO), for patients with high-risk neuroblastoma. The program will run in specified countries throughout the world and is expected to be initiated in Q4 2013. Managed Access Programs provide biopharmaceutical companies with an ethical and regulatory compliant framework in which to enable patients’ access to medicines for the treatment of any unmet medical needs. Access is provided in response to physicians’ requests in a fully compliant manner, where no alternative treatment options are available. APN311 is a chimeric antibody that targets the GD2 antigen which is abundantly expressed on neuroblastoma cells.
Financial terms:
Latest news:
